armored-cart-design-agent

<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

---

name: 'armored-cart-design-agent'

description: 'AI-powered design of armored CAR-T cells with cytokine/chemokine expression for enhanced solid tumor efficacy, including IL-12, IL-15, IL-18, and IL-7 armoring strategies.'

measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.

allowed-tools:

• read_file
• run_shell_command

---

Armored CAR-T Design Agent

The Armored CAR-T Design Agent provides AI-assisted design of next-generation armored CAR-T cells engineered to express cytokines, chemokines, or other enhancing factors. These armored T cells overcome solid tumor challenges including immunosuppressive TME, poor trafficking, and T cell exhaustion, with recent clinical success in lymphoma (IL-18) and ongoing trials with IL-12, IL-15, and IL-7.

When to Use This Skill

• When designing CAR-T cells for solid tumor applications.
• For selecting optimal armoring payloads (cytokines, chemokines).
• To optimize cytokine expression levels and regulation.
• When engineering safety switches for armored constructs.
• For predicting armored CAR-T efficacy and safety profiles.

Core Capabilities

1. Armoring Payload Selection: Choose optimal cytokines for tumor type.

1. Expression Level Optimization: Balance efficacy vs toxicity.

1. Inducible System Design: Engineer regulated expression systems.

1. Safety Switch Integration: Design kill switches and controls.

1. Construct Optimization: Optimize transgene configuration.

1. Efficacy Prediction: Predict enhanced tumor killing.

Armoring Strategies

| Cytokine | Mechanism | Clinical Status | Tumor Types |

|----------|-----------|-----------------|-------------|

| IL-12 | Th1 polarization, IFN-gamma | Phase I/II | Solid tumors |

| IL-15 | T/NK persistence | Phase I/II | Hematologic, solid |

| IL-18 | Inflammasome, IFN-gamma | Phase I (promising) | Lymphoma |

| IL-7 | T cell survival | Phase I | Multiple |

| IL-21 | T cell proliferation | Preclinical | Multiple |

| CCL19/21 | T cell trafficking | Preclinical | Solid tumors |

Construct Architecture Options

| Component | Options | Consideration |

|-----------|---------|---------------|

| Promoter | EF1a, PGK, CAG, NFAT-inducible | Expression level/timing |

| Signal Peptide | Native, IL-2ss, IgK | Secretion efficiency |

| Cytokine | Membrane-bound vs secreted | Local vs systemic |

| Linker | T2A, P2A, IRES | Co-expression efficiency |

| Kill Switch | iCasp9, HSV-TK, CD20 | Safety control |

| Position | Before/after CAR | Expression balance |

Workflow

1. Input: Target tumor type, TME characteristics, CAR design.

1. Payload Selection: Rank armoring strategies for tumor context.

1. Expression Design: Optimize promoter, levels, regulation.

1. Safety Engineering: Add appropriate control switches.

1. Construct Assembly: Generate optimized DNA sequence.

1. Efficacy Prediction: Model enhanced killing and persistence.

1. Output: Optimized armored CAR construct with annotations.

Example Usage

User: "Design an armored CAR-T for pancreatic cancer targeting mesothelin with IL-12 armoring for TME remodeling."

Agent Action:

python3 Skills/Immunology_Vaccines/Armored_CART_Design_Agent/design_armored_cart.py \
    --car_target mesothelin \
    --tumor_type pancreatic \
    --armoring_payload IL-12 \
    --expression_system NFAT_inducible \
    --safety_switch iCasp9 \
    --backbone lentiviral \
    --optimize_codon human \
    --output armored_cart_design/

Output Components

| Output | Description | Format |

|--------|-------------|--------|

| Construct Sequence | Full transgene DNA | .fasta, .gb |

| Construct Map | Annotated visualization | .png, .pdf |

| Expression Model | Predicted levels | .json |

| Safety Analysis | Risk assessment | .json |

| Manufacturing Guide | Production recommendations | .md |

| Predicted Efficacy | Tumor killing model | .json |

IL-12 Armoring Details

| Aspect | Design Choice | Rationale |

|--------|---------------|-----------|

| Configuration | Tethered IL-12 (p70) | Localized, reduced toxicity |

| Expression | NFAT-inducible | Activation-dependent |

| Dose | Low-level expression | Safety optimization |

| Combination | With PD-1 knockout | Enhanced activity |

IL-18 Armoring Details

| Aspect | Design Choice | Rationale |

|--------|---------------|-----------|

| Configuration | Secreted mature IL-18 | Enhanced IFN-gamma |

| Expression | Constitutive or inducible | Context-dependent |

| Clinical Results | Lymphoma responses | Validated approach |

| Combination | With IL-21 | Synergistic |

IL-15 Armoring Details

| Aspect | Design Choice | Rationale |

|--------|---------------|-----------|

| Configuration | Membrane-tethered IL-15/IL-15Ra | Cis-presentation |

| Expression | Constitutive moderate | Persistence without toxicity |

| Benefit | Reduced IL-2 dependence | Manufacturing advantage |

| Safety | Lower CRS risk | Clinical benefit |

AI/ML Components

Payload Selection:

• TME profiling to match cytokine needs
• Multi-objective optimization
• Clinical outcome modeling

Expression Optimization:

• Promoter strength prediction
• Codon optimization
• mRNA stability modeling

Safety Prediction:

• CRS/ICANS risk modeling
• Off-tumor activity prediction
• Systemic cytokine levels

Safety Considerations

| Risk | Mitigation | Implementation |

|------|------------|----------------|

| Cytokine storm | Inducible expression | NFAT promoter |

| Systemic toxicity | Membrane tethering | Localized effect |

| Uncontrolled proliferation | Kill switch | iCasp9 |

| On-target off-tumor | Regulatable CAR | Logic gates |

Clinical Trials (2025-2026)

| Trial | Armoring | Target | Cancer | Status |

|-------|----------|--------|--------|--------|

| NCT03721068 | IL-18 | CD19 | Lymphoma | Phase I (positive) |

| NCT04119024 | IL-12 | GD2 | Neuroblastoma | Phase I |

| NCT03932565 | IL-15/21 | CD19 | B-ALL | Phase I |

| Multiple | IL-7/CCL19 | Various | Solid | Preclinical |

Prerequisites

• Python 3.10+
• Biopython for sequence handling
• CAR design databases
• Codon optimization tools
• Structure prediction (optional)

Related Skills

• CART_Design_Optimizer_Agent - Base CAR optimization
• NK_Cell_Therapy_Agent - NK cell engineering
• Cytokine_Storm_Analysis_Agent - Safety analysis
• TCell_Exhaustion_Analysis_Agent - Exhaustion prevention

Manufacturing Considerations

| Aspect | Armored CAR Challenge | Solution |

|--------|----------------------|----------|

| Vector Size | Larger transgene | Optimize construct |

| Transduction | Lower efficiency | Increase MOI |

| Expansion | Cytokine effects | Tune expression |

| Characterization | Complex phenotype | Enhanced QC |

Special Considerations

1. Tumor Type Matching: Different tumors need different armoring
2. Expression Timing: Constitutive vs inducible tradeoffs
3. Dose Finding: Balance efficacy vs toxicity
4. Combination: Consider with checkpoint knockout
5. Manufacturing: Larger constructs affect production

Efficacy Enhancement Mechanisms

| Mechanism | Cytokine | Effect |

|-----------|----------|--------|

| Persistence | IL-15, IL-7 | Longer survival |

| TME Remodeling | IL-12 | M2→M1, DC activation |

| Bystander Killing | IL-18 | Enhanced IFN-gamma |

| Trafficking | CCL19/21 | T cell recruitment |

| Anti-exhaustion | IL-21 | Stem-like maintenance |

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->